• Disc Medicine released an investor presentation outlining late-stage plans for bitopertin in erythropoietic protoporphyria, with Phase 3 APOLLO readout expected Q4 2026.
• APOLLO enrolled 183 EPP or XLP patients ages 12+ in a 6-month, randomized, double-blind, placebo-controlled trial using a 60 mg dose.
• Co-primary endpoints target pain-free sunlight exposure in month 6, plus % change in whole-blood metal-free PPIX at 6 months.
• Phase 2 AURORA highlighted a 40% PPIX reduction vs baseline, a 75% drop in phototoxic reactions vs placebo, 86% reporting “much better.”
• Pipeline focus remains heme and iron biology, including selcodebart for anemia indications, plus DISC-3405 for polycythemia vera and sickle cell disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.